Skip to main content

Table 2 Baseline variables predictive of WPAI:SHP subscales at 6 and 12 months in 1003 AS patients

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Predictor Odds ratio (95% CI)
 Outcome: absenteeism  
  Fatigue 1.18 (0.92 to 1.51)
  % work time missed due to AS (> 0 vs 0) 4.59 (2.91 to 7.25)
  Anxiety/depression Some vs none 1.77 (1.12 to 2.80)
Extreme vs none 0.87 (0.26 to 2.86)
Extreme vs some 0.49 (0.15 to 1.57)
  Visit 12 months vs 6 months 1.001 (0.70 to 1.44)
Predictor Standardized beta-coefficient (β) (95% CI)
 Outcome: presenteeism  
  Fatigue 3.75 (2.14 to 5.36)
  Male vs female −4.65 (−7.62 to −1.68)
  Age (years) 4.48 (3.07 to 5.89)
  CRP −1.83 (−3.53 to −0.13)
  % impairment while working due to AS 6.25 (4.67 to 7.82)
  Visit 12 months vs 6 months −0.99 (−2.57 to 0.60)
 Outcome: Work productivity loss
  Fatigue 1.81 (−0.40 to 4.02)
  Male vs female −3.57 (−7.29 to 0.15)
  Age (years) 5.22 (3.52 to 6.93)
  Pain 2.77 (0.34 to 5.20)
  Pain at 12 months vs pain at 6 months −2.49 (−4.49 to −0.49)
  % overall work impairment due to AS 6.62 (4.53 to 8.71)
  Anxiety/depression Some vs none 3.76 (0.09 to 7.42)
Extreme vs none 12.32 (1.38 to 23.26)
  Visit 12 months vs 6 months −1.42 (−3.42 to 0.59)
 Outcome: Activity impairment
  Fatigue 2.62 (1.26 to 3.98)
  Age (years) 5.07 (3.96 to 6.19)
  CRP −2.76 (−3.85 to −1.67)
  % activity impairment due to AS 8.51 (7.14 to 9.87)
  Anxiety/depression Some vs none 3.27 (0.85 to 5.68)
Extreme vs none 10.74 (5.35 to 16.14)
  Visit 12 months vs 6 months −1.10 (−2.35 to 0.15)
  1. AS, ankylosing spondylitis; CI, confidence interval; CRP, C-reactive protein; RA, rheumatoid arthritis; VAS, visual analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems